Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

FGFR2

4 articles · Resources: NCBI Gene, OncoKB

Clinical · Molecular biology

Upfront Comprehensive Genomic Profiling in Advanced Biliary Tract Cancer: Real-World Implementation and Clinical Outcomes

Hussung S, Roth M, Akhoundova D, et al.

Cancer medicine

This real-world study evaluated the implementation of upfront comprehensive genomic profiling (CGP) in 80 patients with advanced biliary tract cancer (BTC). Clinically actionable alterations were detected in 52.5% of cases—predominantly in IDH1, FGFR2, ERBB2, KRAS G12C, and BRAF—with anatomical enrichment of FGFR2 and IDH1 in intrahepatic cholangiocarcinoma. Matched targeted therapies were administered to 11 of the 42 actionable patients, yielding a significantly longer treatment duration compared with the preceding systemic line (p = 0.0391) and enabling secondary surgical resection in two patients. These findings confirm the clinical feasibility and value of upfront CGP in BTC while emphasizing the critical need to bridge the gap between biomarker identification and drug access.

Clinical · Bioinfo & AI

Computational screening of oncogenic genetic variations in tumor suppressor proteins driving gastric cancer pathogenesis

Mim FF, Sumiya TA, Khanam R, et al.

PloS one

This study employed a deep learning-based graph neural network model to identify genes and pathogenic genetic variations driving gastric cancer pathogenesis. Researchers focused on tumor suppressor proteins exhibiting both dysregulated expression and high mutation propensity. The model identified 1,886 relevant genes, with TP53, ERBB2, CDH1, and APC emerging as prominent hub genes. Missense and nonsense variants in TP53, CDH1, and APC were validated, affecting post-translational modification sites and correlating with altered patient survival. The study also highlighted EZH2 and miR-129-5p as key regulators and the dysregulation of oncogenes like CCNE1/2 and FGFR2.

Clinical · Molecular biology

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

Cowzer D, Walch H, Atri P, et al.

Clinical cancer research

This study analyzed a cohort of 1,254 patients with biliary tract cancer to assess the utility of targeted NGS molecular profiling. It revealed that 59% of patients harbored at least one OncoKB alteration, and 32.2% had level 1/2 alterations, with varying frequencies across tumor locations. Targeted therapies were associated with improved progression-free survival but not overall survival. The study also identified co-occurring alterations and acquired resistance mechanisms, such as ERBB2 loss or alterations in the RAS, MEK, MET, MYC, and CDKN2A pathways. These findings highlight genomic heterogeneity and the importance of precision medicine in informing future drug development efforts.

Clinical · Molecular biology

Gene Expression Profiling of EGFR, FGFR2, PIK3CA, PTEN, SMAD4, STK11, and TP53 in Cell-Free RNA From Exhaled Breath Condensate: Diagnostic, Prognostic, and Therapeutic Implications in Advanced Lung Adenocarcinoma

Latifova S, Genis U, Karakus HS, et al.

Cancer reports (Hoboken, N.J.)

This prospective study evaluated gene expression profiling of seven genes (EGFR, FGFR2, PIK3CA, PTEN, SMAD4, STK11, TP53) in cell-free RNA (cfRNA) from exhaled breath condensate (EBC) in patients with advanced lung adenocarcinoma. Results indicated that PIK3CA showed the best diagnostic performance in distinguishing patients from healthy controls. High expression of FGFR2 and PIK3CA was associated with significantly shorter overall survival, highlighting their prognostic relevance. EGFR expression demonstrated a strong correlation between EBC and plasma, and low EGFR expression was linked to longer survival in patients receiving chemotherapy alone. This non-invasive EBC-based approach offers potential for molecular characterization and patient stratification.